| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11400101 | GLENMARK SPECIALTY | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US10765686 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US10758550 | GLENMARK SPECIALTY | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US10646500 | GLENMARK SPECIALTY | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US10548907 | GLENMARK SPECIALTY | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US10016443 | GLENMARK SPECIALTY | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US10517880 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US9750754 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US9078923 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US9937189 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US10376526 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US9370483 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US10561672 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(10 years from now) | |
| US11679210 | GLENMARK SPECIALTY | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
Sep, 2038
(14 years from now) | |
Ryaltris is owned by Glenmark Specialty.
Ryaltris contains Mometasone Furoate; Olopatadine Hydrochloride.
Ryaltris has a total of 14 drug patents out of which 0 drug patents have expired.
Ryaltris was authorised for market use on 13 January, 2022.
Ryaltris is available in spray, metered;nasal dosage forms.
Ryaltris can be used as treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate to a pediatric patient, treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate, method of delivering a combination of olopatadine hydrochloride and mometasone furoate to a nasal airway.
The generics of Ryaltris are possible to be released after 03 September, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Jan 13, 2025 |
Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 January, 2022
Treatment: Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate; Method of delivering a combination of olopatadine hydrochloride and m...
Dosage: SPRAY, METERED;NASAL
RYALTRIS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic